For research use only. Not for therapeutic Use.
AN-2690（Cat No.:I002281）is an investigational antifungal agent, specifically targeting dermatophytes responsible for fungal infections such as onychomycosis. It works by inhibiting the enzyme lanosterol 14α-demethylase, which is crucial for the synthesis of ergosterol, a key component of fungal cell membranes. The inhibition of ergosterol production leads to disruption of fungal cell membrane integrity, effectively stopping fungal growth. AN-2690 has shown promising activity against a range of dermatophytes, offering a potential treatment option for patients with difficult-to-treat skin and nail infections.
| Catalog Number | I002281 |
| CAS Number | 174671-46-6 |
| Synonyms | 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole |
| Molecular Formula | C7H6BFO2 |
| Purity | ≥95% |
| Target | Antibiotic |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole |
| InChI | InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2 |
| InChIKey | LFQDNHWZDQTITF-UHFFFAOYSA-N |
| SMILES | B1(C2=C(CO1)C=C(C=C2)F)O |
| Reference | </br>1:Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults. Gupta AK, Daigle D.Expert Rev Anti Infect Ther. 2014 Jul;12(7):735-42. doi: 10.1586/14787210.2014.915738. Epub 2014 Jun 4. Review. PMID: 24894552 </br>2:AN-2690, a novel antifungal for the topical treatment of onychomycosis. Barak O, Loo DS.Curr Opin Investig Drugs. 2007 Aug;8(8):662-8. Review. PMID: 17668368 |
